Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Int J Clin Pharm. 2021 Jun;43(3):541-548. doi: 10.1007/s11096-020-01160-8. Epub 2020 Oct 9.
Background The leukotriene receptor antagonist montelukast has been shown to rejuvenate aged brains in rats; however, data on humans are still scarce. Objective To investigate if montelukast may alleviate degenerative neurological changes using a register data. Setting Norwegian registry data analyses. Method The present observational study was based on data from the Norwegian Prescription Database and the Tromsø Study. The former has information regarding the use of prescription medicine; the latter includes tests for brain function such as subjective memory and finger-tapping. Multivariate linear regression analyses were performed to see how the use of various medications correlated with the test results, correcting for likely confounders. Main outcome measure Results on seven different tests considered relevant for neurological health were used as outcome. Results Previous use of montelukast correlated with improved scores on cognitive or neurological functioning (F = 2.20, p = 0.03 in a multivariate test). A range of other medications were tested with the same algorithm, including drugs acting on the immune system, but none of them correlated with (overall) significantly improved test results. Conclusion The present data suggest that montelukast may alleviate degenerative neurological changes associated with human aging.
白三烯受体拮抗剂孟鲁司特已被证明可使大鼠衰老的大脑恢复活力；然而，人类的数据仍然很少。目的：使用登记数据调查孟鲁司特是否可以减轻神经退行性变化。设置：挪威登记数据分析。方法：本观察性研究基于来自挪威处方数据库和特罗姆瑟研究的数据。前者提供有关处方药使用的信息；后者包括用于测试大脑功能的测试，例如主观记忆和手指敲击。进行多元线性回归分析，以了解各种药物的使用与测试结果之间的相关性，同时校正可能的混杂因素。主要观察指标：将七个被认为与神经健康相关的不同测试的结果用作结果。结果：孟鲁司特的既往使用与认知或神经功能的评分改善相关（多元检验中 F=2.20，p=0.03）。使用相同的算法测试了一系列其他药物，包括作用于免疫系统的药物，但没有一种药物与（整体）显著改善的测试结果相关。结论：本数据表明，孟鲁司特可能减轻与人类衰老相关的神经退行性变化。
